LncRNA MSC‐AS1 motivates the development of melanoma by binding to miR‐302a‐3p and recruiting IGF2BP2 to elevate LEF1 expression

Melanoma is considered as the most common malignancy among skin cancers. The roles of many long non‐coding RNAs (lncRNAs) have been clearly identified in multiple tumors. Nevertheless, lncRNA MSC antisense RNA 1 (MSC‐AS1) has not been deeply investigated melanoma. In the present study, RT‐qPCR and w...

Full description

Saved in:
Bibliographic Details
Published in:Experimental dermatology 2021-12, Vol.30 (12), p.1764-1774
Main Authors: Ma, Yan, Jin, Yuanyuan, Li, Can, Liu, Yilun, Wang, Dehuai
Format: Article
Language:English
Subjects:
Animals
Antisense RNA
Cell Line, Tumor
Cell migration
Cell Movement
Cell Proliferation
Female
Gene Expression Regulation, Neoplastic
Humans
IGF2BP2
Insulin
LEF1
Lymphoid Enhancer-Binding Factor 1 - metabolism
Malignancy
Melanoma
Melanoma - genetics
Melanoma - physiopathology
Mesenchyme
Mice
Mice, Nude
MicroRNAs - metabolism
miRNA
miR‐302a‐3p
mRNA
MSC‐AS1
Non-coding RNA
RNA, Long Noncoding - metabolism
RNA-Binding Proteins - metabolism
Skin cancer
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Melanoma is considered as the most common malignancy among skin cancers. The roles of many long non‐coding RNAs (lncRNAs) have been clearly identified in multiple tumors. Nevertheless, lncRNA MSC antisense RNA 1 (MSC‐AS1) has not been deeply investigated melanoma. In the present study, RT‐qPCR and western blot analyses were used to measure the expression of RNAs and proteins. Functional and in vivo assays were implemented to detect the function of genes in melanoma. RNA pull‐down, RIP and luciferase reporter assays were applied for determining interactions between RNA and protein molecules. It was observed that MSC‐AS1 and lymphoid enhancer‐binding factor 1 (LEF1) were remarkably up‐regulated while microRNA‐302a‐3p (miR‐302a‐3p) down‐regulated in melanoma cell lines. The silencing of MSC‐AS1 hindered cell proliferation, migration and epithelial‐mesenchymal transition (EMT) in vitro and tumor growth in vivo. Furthermore, MSC‐AS1 regulated LEF1 expression through sponging miR‐302a‐3p and recruiting insulin like growth factor 2 mRNA‐binding protein 2 (IGF2BP2). Eventually, LEF1 overexpression rescued cell progression impaired by MSC‐AS1 knock‐down. In summary, our research identified the MSC‐AS1/miR‐302a‐3p/IGF2BP2/LEF1 axis in melanoma development, which indicated that MSC‐AS1 is a potential biomarker in the treatment of melanoma.
ISSN:0906-6705
1600-0625
DOI:10.1111/exd.14427